Lyra Therapeutics Inc.

NASDAQ: LYRA · Real-Time Price · USD
6.84
-0.26 (-3.66%)
At close: Aug 15, 2025, 3:09 PM

Lyra Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
40.58M 22.35M 32.55M 45.75M
Short-Term Investments
n/a 80.4M 65.34M n/a
Long-Term Investments
1.99M 1.39M 1.39M 329K
Other Long-Term Assets
n/a 1.11M 3.28M 762K
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
2.45M 2.07M 2.94M n/a
Total Current Assets
43.02M 104.82M 100.83M 47.92M
Property-Plant & Equipment
21.33M 35.28M 4.47M 5.86M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
23.32M 37.78M 9.14M 6.95M
Total Assets
66.35M 142.6M 109.97M 54.87M
Account Payables
1.18M 3.13M 2.62M 3.13M
Deferred Revenue
398K 1.66M 1.27M 9.79M
Short-Term Debt
n/a n/a 3.51M 1.07M
Other Current Liabilities
6.93M 1.23M 584K 755K
Total Current Liabilities
12.63M 19.6M 14.47M 18.25M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a 14.08M 1.93M
Total Long-Term Liabilities
42.12M 33.58M 14.74M 2.31M
Total Liabilities
54.75M 53.18M 29.21M 20.55M
Total Debt
34.38M 26.88M 4.18M 1.45M
Common Stock
65K 57K 32K 13K
Retained Earnings
-404.79M -311.36M -248.68M -193.4M
Comprehensive Income
n/a 33K 10K n/a
Shareholders Equity
11.59M 89.42M 80.75M 34.32M
Total Investments
1.99M 80.4M 65.34M 329K